Long-Term Data Support Cilta-Cel Use in R/R Multiple Myeloma: Sundar Jagannath, MBBS
June 25th 2025Long-term CARTITUDE-1 data show ciltacabtagene autoleucel (cilta-cel) may offer lasting remission and survival in relapsed/refractory multiple myeloma, according to Sundar Jagannath, MBBS, of the Icahn School of Medicine at Mount Sinai.
Atrasentan Has Promising Long-Term Potential in IgA Nephropathy: Richard Lafayette, MD, FACP
June 24th 2025Richard Lafayette, MD, FACP, explains why a REMS program is not required for the endothelin A receptor antagonist and how patients may need to adjust should final ALIGN trial data fail to show a clinical benefit of atrasentan.
Health Equity & Access Weekly Roundup: June 23, 2025
June 23rd 2025From widening racial health disparities and abortion care restrictions to coverage losses, leadership gaps in addressing social needs, and worsening workforce shortages, the urgent need to improve health equity is underscored in the US.
Culture Key to Data Collection of Sexual Orientation and Gender Identity in Cancer Care
June 23rd 2025This research highlights the key factors, like leadership buy-in, mandatory protocols, and electronic health record workflows, that influence the effective collection of data on sexual orientation and gender identity in outpatient oncology clinics to improve patient-centered care.
Breaking Down Taletrectinib’s FDA Approval: Jorge J. Nieva, MD
June 20th 2025In this interview with TRUST-I and TRUST-II trial investigator, Jorge J. Nieva, MD, USC Keck School of Medicine, he walks through the design of the trials, the results that supported the FDA approval, and taletrectinib’s potential to redefine first-line therapy.
CARTITUDE-4 Data Solidify Cilta-cel’s Role in RRMM: Surbhi Sidana, MD, MBBS
June 19th 2025Surbhi Sidana, MD, MBBS, director of the Myeloma Disease Focused Group at Stanford University, provides a reintroduction to CARTITUDE-4 and insight on how this phase 3 investigation builds on previous findings of CAR T vs standard-of-care findings in relapsed/refractory multiple myeloma (RRMM)
Democratic Doctors Caucus Reaffirms EMTALA Amid Trump's CMS Policy Reversal on Abortion Care
June 18th 2025Democratic leaders assert the Emergency Medical Treatment and Labor Act (EMTALA) remains vital for emergency care, countering confusion from recent policy changes affecting abortion rights and patient safety.